Major Study Finds Cannabis Ineffective for Anxiety, Depression, and PTSD

A comprehensive analysis published in The Lancet challenges the widespread use of medicinal cannabis for mental health conditions. The University of Sydney study—the largest review to date—found no evidence that cannabis effectively treats anxiety, depression, or PTSD, despite these being primary reasons millions use it medically.

The timing is significant given that 27% of adults aged 16-65 in North America use cannabis medically, with roughly half targeting mental health symptoms. Lead researcher Dr. Jack Wilson warns that routine cannabis use might cause more harm than good, potentially worsening mental health outcomes through increased psychosis risk and cannabis dependency while delaying access to proven treatments.

The review did identify some limited benefits for specific conditions including cannabis dependency, autism, insomnia, and Tourette's syndrome. However, researchers emphasized the supporting evidence remains weak and rarely justifies use without robust medical supervision. For substance use disorders, results were mixed—cannabis showed potential for treating cannabis dependency when combined with therapy, but increased cravings in people with cocaine-use disorder.

These findings have important implications for health optimization strategies. While cannabis has proven benefits for certain conditions like epilepsy-related seizures and multiple sclerosis spasticity, the evidence for mental health applications falls short of supporting widespread use. The research suggests people seeking mental health treatment should prioritize evidence-based therapies rather than cannabis-based approaches, which may inadvertently delay recovery and introduce additional risks.